EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cumberland Pharmaceuticals's Enterprise Value is $38.28 Mil.
Cumberland Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.72 Mil. Therefore, Cumberland Pharmaceuticals's EV-to-FCF for today is -22.29.
The historical rank and industry rank for Cumberland Pharmaceuticals's EV-to-FCF or its related term are showing as below:
CPIX'
s EV-to-FCF Range Over the Past 10 Years
Min: -181.19 Med: 5.98 Max: 239.29
Current: -22.29
During the past 13 years, the highest EV-to-FCF of Cumberland Pharmaceuticals was 239.29. The lowest was -181.19. And the median was 5.98.
CPIX's EV-to-FCF is ranked worse than 100% of 552
companies
in the Drug Manufacturers industry
Industry Median: 25.86
vs CPIX: -22.29
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cumberland Pharmaceuticals's EV-to-FCF
For the Drug Manufacturers - Specialty & Generic subindustry, Cumberland Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cumberland Pharmaceuticals's EV-to-FCF Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cumberland Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Cumberland Pharmaceuticals's EV-to-FCF falls into.
Cumberland Pharmaceuticals's current Enterprise Value is $38.28 Mil.
Cumberland Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.72 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cumberland Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Cumberland Pharmaceuticals's share price for today is $2.42.
Cumberland Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.770.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cumberland Pharmaceuticals EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Cumberland Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CPIX has been successfully added to your 